中新网广州8月8日电 (记者 蔡敏婕)创新降脂药8日在广州、上海、北京等多地开出首批处方，为心血管疾病患者带来原研进口的联合降脂新选择。
当天，欧加隆旗下创新降脂单片复方制剂益立妥[通用名：依折麦布阿托伐他汀钙片(Ⅱ)]在中国医学科学院阜外医院、上海交通大学医学院附属瑞金医院、北京和睦家医院、广州和睦家医院等医院开出首批处方，有望助力更多血脂异常患者从降脂达标中获益。
当前，心血管疾病依然是导致我国居民死亡的首要原因。而在动脉粥样硬化性心血管疾病的防治中，降低低密度脂蛋白胆固醇是关键。
“面对患病率高、治疗率低、达标率低的血脂管理现状，临床亟需找到适合我国疾病发展现状的治疗方案，帮助不同病情的血脂异常患者针对性解决问题。”中国医学科学院阜外医院教授李建军指出，“近年来，降脂药物的联合使用已成为临床血脂管理的基本趋势，创新降脂单片复方制剂进一步丰富了联合治疗选择，这对于提升患者降脂达标率具有重要意义。”
此外，血脂管理重在长期规范用药，但“难以坚持”成为降脂治疗过程中的一大障碍。尤其是对于合并有高血压、糖尿病等疾病的血脂异常患者，每天需服用的药物往往是“一吃一大把”，容易出现忘服、漏服等现象，导致治疗依从性降低，增加心血管事件的风险。
上海交通大学医学院附属瑞金医院教授陈桢玥表示：“在临床血脂管理中，治疗依从性一直是主要挑战之一，依折麦布阿托伐他汀钙片等单片复方制剂带来降脂治疗新选择，促进长期规范用药。期待在更多创新治疗的助力下，助推我国心血管疾病整体防治水平的持续提升。”
“对于血脂异常的患者，降脂达标是预防和治疗心血管疾病的关键举措。”浙江求是心血管病医院院长沈法荣表示，“作为公立医疗服务的有益补充，社会办医在提供基本医疗卫生服务的同时，助力为患者提供更全面的治疗方案，以满足群众多层次、多样化的健康服务需求。”
此次创新降脂药的开出首批处方，不仅为心血管疾病患者提供了新的治疗选择，也为我国心血管疾病的防治工作带来了新的希望。通过创新药物的应用，有望进一步提升患者的治疗依从性，降低心血管疾病的发生风险，为患者带来更多的健康福祉。
英语如下：
Innovative Lipid-lowering Drug Opens New Chapter: Cardiovascular Disease Patients Welcome New Options for Combined Lipid-lowering Therapy
Keywords: Lipid-lowering drugs, Combined treatment, Cardiovascular disease
Beijing, August 8 (Xinhua) — On August 8, the first prescriptions for an innovative lipid-lowering drug were issued in multiple cities including Guangzhou, Shanghai, and Beijing, offering cardiovascular disease patients a new choice of original imported combined lipid-lowering therapy.
On the same day, the innovative lipid-lowering single-tablet fixed-dose combination product Evolocumab/Atorvastatin Calcium Tablets (II), marketed by Hexal, was prescribed for the first time at the Fuwai Hospital of the Chinese Academy of Medical Sciences, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Beijing United Family Hospital, and Guangzhou United Family Hospital, among others. This is expected to help more patients with abnormal lipid levels benefit from achieving lipid targets.
Currently, cardiovascular diseases remain the leading cause of death among Chinese residents. In the prevention and treatment of atherosclerotic cardiovascular diseases, lowering low-density lipoprotein cholesterol is crucial.
“Given the high prevalence of the disease, low treatment rate, and low achievement rate in lipid management, there is an urgent need to find suitable treatment strategies that match the current disease landscape in China, helping different levels of lipid abnormalities to address specific issues,” noted Professor Li Jianjun from the Fuwai Hospital of the Chinese Academy of Medical Sciences. “In recent years, the combination use of lipid-lowering drugs has become a basic trend in clinical lipid management, and the innovative single-tablet fixed-dose combination product further enriches the options for combined treatment, which is of great significance for improving the achievement rate of lipid targets.”
Furthermore, the management of lipid levels is crucial for long-term and standardized medication, but “difficulty in adherence” has become a significant obstacle in the lipid treatment process. Especially for patients with lipid abnormalities who also have conditions such as hypertension and diabetes, the daily medications often amount to “a handful,” making it easy to forget or miss doses, thereby reducing treatment adherence and increasing the risk of cardiovascular events.
Professor Chen Zhenyu from Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, said, “In clinical lipid management, adherence has always been one of the main challenges. Products like Evolocumab/Atorvastatin Calcium Tablets offer new choices for lipid treatment, promoting long-term and standardized use. We look forward to more innovative treatments to help boost the overall level of cardiovascular disease prevention and treatment in China.”
“For patients with lipid abnormalities, achieving lipid targets is a key measure for the prevention and treatment of cardiovascular diseases,” said Dr. Shen Falong, the President of Zhejiang Qiu Shi Cardiovascular Hospital. “As a beneficial supplement to public healthcare services, private medical care provides basic healthcare services while assisting in offering more comprehensive treatment plans to meet the diverse health service needs of the public.”
The issuance of the first prescriptions for this innovative lipid-lowering drug not only provides new treatment options for cardiovascular disease patients but also brings new hope to the prevention and treatment of cardiovascular diseases in China. Through the application of innovative drugs, it is expected to further improve treatment adherence and reduce the risk of cardiovascular diseases, bringing more health benefits to patients.
【来源】http://www.chinanews.com/life/2024/08-08/10265899.shtml
Views: 0